Thymoquinone: fifty years of success in the battle against cancer models
Schneider-Stock R, Fakhoury IH, Zaki AM, El Baba C, Gali-Muhtasib HU (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: Elsevier
Book Volume: 19
Pages Range: 18-30
Journal Issue: 1
DOI: 10.1016/j.drudis.2013.08.021
Abstract
Thymoquinone (TQ), the main active constituent of black seed essential oil, exhibits promising effects against inflammatory diseases and cancer. TQ, modulates signaling pathways that are key to cancer progression, and enhances the anticancer potential of clinical drugs while reducing their toxic side effects. Considering that TQ was isolated 50 years ago, this review focuses on TQ's chemical and pharmacological properties and the latest advances in TQ analog design and nanoformulation. We discuss our current state of knowledge of TQ's adjuvant potential and in vivo antitumor activity and highlight its ability to modulate the hallmarks of cancer.
Authors with CRIS profile
Regine Schneider-Stock
Professur für Experimentelle Tumorpathologie
Chirine El Baba
Professur für Experimentelle Tumorpathologie
Involved external institutions
Lebanon (LB)How to cite
APA:
Schneider-Stock, R., Fakhoury, I.H., Zaki, A.M., El Baba, C., & Gali-Muhtasib, H.U. (2014). Thymoquinone: fifty years of success in the battle against cancer models. Drug Discovery Today, 19(1), 18-30. https://doi.org/10.1016/j.drudis.2013.08.021
MLA:
Schneider-Stock, Regine, et al. "Thymoquinone: fifty years of success in the battle against cancer models." Drug Discovery Today 19.1 (2014): 18-30.
BibTeX: Download